{"id":126,"date":"2023-09-20T12:48:35","date_gmt":"2023-09-20T03:48:35","guid":{"rendered":"http:\/\/www.lifescience.shokubai.co.jp\/home\/service03\/"},"modified":"2026-04-08T17:15:51","modified_gmt":"2026-04-08T08:15:51","slug":"dds-research","status":"publish","type":"page","link":"https:\/\/www.lifescience.shokubai.co.jp\/en\/dds-research\/","title":{"rendered":"Support for Drug Development"},"content":{"rendered":"\n<section class=\"service03_contents_01 service_page_contents inner-container\">\n  <ul>\n    <li class=\"list_3\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n          Peptides that deliver siRNA<br><span>DDS technology for selectively delivering siRNA to pancreatic cancer, etc.<\/span>\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n          Fol-Dab8 is innovative DDS technology that forms a complex with siRNA and delivers siRNA to folate receptor-expressing cells (pancreatic cancer, brain tumors, breast cancer, etc.).\n          Fol-Dab8 is available in a form of complex with siRNA of any sequence.<br \/>\n          *This technology was co-developed with Dr. Takeshi Wada of Tokyo University of Science and Dr. Keisuke Taniuchi of Kochi University.<br \/>\n          *Fol-Dab8 is an abbreviation for 2,4-diaminobutyric acid (Dab) octamer with folic acid (Folate) linked via a linker.<br \/>\n        <\/p>  \n        <div class=\"btnBox pc\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/04\/Fol-Dab8_en_2025.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About Fol-Dab8<\/a>\n        <\/div>\n        <div class=\"btnBox sp-f\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/04\/Fol-Dab8_en_2025.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About Fol-Dab8<\/a>\n        <\/div>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox tab-hide\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/Fol-Dab8_en.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/1d715ba4c163e4537712deeb22b376fd.png\" alt=\"\">\n        <\/picture>\n        <picture class=\"imgBox tab-t\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/Fol-Dab8_en_sp.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/1d715ba4c163e4537712deeb22b376fd.png\" alt=\"\">\n        <\/picture>\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n\n    <li class=\"list_3\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n          New biocompatible polymer(For DDS and others)<br><span>A new option following polyethylene glycol.<\/span>\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n          A novel biocompatible polymer &#8220;PGLMMA&#8221; offers numerous advantages, such as being less likely to induce IgM antibody production and maintaining blood retention even after multiple doses.<br\/>\n         *PGLMMA is an abbreviation for poly (glycerol monomethacrylate). \n        <\/p>\n        <div class=\"btnBox pc\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/04\/PGLMMA_en_2025.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About PGLMMA<\/a>\n        <\/div>\n        <div class=\"btnBox sp-f\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/04\/PGLMMA_en_2025.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About PGLMMA<\/a>\n        <\/div>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/PGLMMA_en.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/12\/170f25249c652c2a36b5febc3e8ad474.png\" alt=\"\">\n        <\/picture>\n\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n\n    <li class=\"list_3\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n         Heteroduplex Oligonucleotides<span> (HDO)<\/span>\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n Heteroduplex oligonucleotide (HDO) is the third platform technology for mRNA Therapeutics following short interfering RNA (siRNA) and single-stranded antisense oligonucleotide (ASO), which serves as a therapeutic agent for the modulation of specific genes at the post-transcriptional level.\u00a0HDO is an artificial functioning nucleic acids composed of an antisense strand (gapmer, mixmer, PMO etc.) that binds to a transcript of a target gene and a carrier strand (RNA) that is complementary to the antisense strand.\u00a0Since a ligand (receptor ligands, antibodies, lipids, etc.) is bound to the carrier strand, various ligands can be introduced without affecting the activity of the antisense strand enabling cell-specific delivery. HDO has high nuclear localization and low toxicity compared to ASO.\n        <\/p>\n       <div class=\"btnBox pc\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/04\/HDO_trial_en_2025.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About HDO trial service<\/a>\n        <\/div>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img03.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img03.png\" alt=\"\">\n        <\/picture>\n        <div class=\"innerBox_01\">\n          <picture class=\"imgBox\">\n            <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/02\/service03_img03-2.webp\" type=\"image\/webp\">\n            <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2024\/02\/service03_img03-2-1.png\" alt=\"\">\n          <\/picture>\n          <ul class=\"lower_contents_summary\">\n            <li>Rena Therapeutics uses heteroduplex oligonucleotide (HDO) technology as its base technology. HDO technology was co-developed by Professor Takanori Yokota of Institute of Science Tokyo and Professor Satoshi Obika of Osaka University. <\/li>\n            <li>Rena Therapeutics is a subsidiary of Nippon Shokubai.<\/li>\n          <\/ul>\n        <\/div><!-- \/.innerBox -->\n         <div class=\"btnBox sp-f\">\n           <a href=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/uploads\/2026\/04\/HDO_trial_en_2025.pdf\" target='_blank' class=\"btn_01 btn_01_c\" rel=\"noopener\">About HDO trial service<\/a>\n        <\/div>\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n    <li class=\"list_4\">\n      <div class=\"textContent\">\n        <h2 class=\"lower_contents_title\">\n          Boranophosphate Oligonucleotides\n        <\/h2>\n        <p class=\"lower_contents_summary\">\n          We are developing chemical synthesis techniques and practical manufacturing methods for boranophosphate oligonucleotides, which have a new structure to replace conventional phosphorothioate oligonucleotides. \n        <\/p>\n      <\/div><!-- \/.textContent -->\n\n      <div class=\"imgContent\">\n        <picture class=\"imgBox\">\n          <source srcset=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img04.webp\" type=\"image\/webp\">\n          <img decoding=\"async\" src=\"https:\/\/www.lifescience.shokubai.co.jp\/home\/wp-content\/themes\/nipponshokubai\/img\/service\/service03_img04.png\" alt=\"\">\n        <\/picture>\n      <\/div><!-- \/.imgContent -->\n    <\/li>\n  <\/ul>\n\n\n<\/section><!-- \/.service01_contents_01 -->\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peptides that deliver siRNADDS technology for selectively delivering siRNA to pancreatic cancer, etc. Fol-Dab8 is innovative DDS technology that forms a complex with siRNA and delivers siRNA to folate receptor-expressing cells (pancreatic cancer, brain tumors, breast cancer, etc.). Fol-Dab8 is available in a form of complex with siRNA of any sequence. *This technology was co-developed [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-126","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages\/126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/comments?post=126"}],"version-history":[{"count":1,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages\/126\/revisions"}],"predecessor-version":[{"id":2281,"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/pages\/126\/revisions\/2281"}],"wp:attachment":[{"href":"https:\/\/www.lifescience.shokubai.co.jp\/en\/wp-json\/wp\/v2\/media?parent=126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}